Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Journal of Pharmaceutical Health Care and Sciences|December 18, 2018
Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, et al.Frontiers in Oncology|November 25, 2021
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective StudyToshiki Ogiwara, Hitoshi Kawazoe, Saeka Egami, et al.International Journal of Clinical Oncology|October 18, 2017
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapyTakako Yanai, Satoru Iwasa, Hironobu Hashimoto, et al.International Journal of Clinical Oncology|October 6, 2025
Chemotherapy-related hand-foot syndrome and hand-foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study teamYohei Iimura, Hirotoshi Iihara, Yoshitaka Saito, et al.International Journal of Clinical Oncology|September 1, 2025
Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study TeamYohei Iimura, Hirotoshi Iihara, Yoshitaka Saito, et al.International Journal of Hematology|March 25, 2025
Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host diseaseYoshihiro Inamoto, Ayumu Ito, Toshihisa Nakashima, et al.The Lancet. Oncology|December 16, 2019
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialHironobu Hashimoto, Masakazu Abe, Osamu Tokuyama, et al.European Journal of Clinical Pharmacology|January 18, 2022
Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitantHideyuki Hibino, Naomi Sakiyama, Yoshinori Makino, et al.JAMA Network Open|May 2, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical TrialMasakazu Abe, Takuhiro Yamaguchi, Yukiyoshi Fujita, et al.Cancer Medicine|March 19, 2026
Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid TumorYukiko Shimoda Igawa, Tatsuya Yoshida, Jun Sato, et al.Pageof 8